New shot-based leukemia treatment enters phase 2 trial for hard-to-treat patients
NCT ID NCT07222579
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 21 times
Summary
This study tests a drug called blinatumomab, given as a shot under the skin, for adults with a rare type of leukemia (MPAL) that has a specific marker (CD19). It includes three groups: newly diagnosed patients who cannot have strong chemotherapy, patients in remission with leftover cancer cells, and patients whose cancer has returned or not responded to treatment. The goal is to see if the drug can improve survival or achieve complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West Virginia University Cancer Institute
RECRUITINGMorgantown, West Virginia, 26506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.